telehealth

Q2 revenue of $753.2 million topped estimates by 7.8 percent, but a trimmed full-year adjusted EBITDA forecast sent shares down 9.7 percent.

Teladoc's stretched valuation and profitability challenges make it a risky bet as telehealth adoption normalizes

Hims & Hers Health, Inc. stock rallied sharply today after the U.S. government confirmed it would reassess the regulatory framework for popular peptides, signaling a substantial expansion opportunity for the telehealth provider.